CD8-reduced T cells for MDS/AML in MPN progression
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-01 — CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene: cross-connection with icasp9-allodepleted-tcells-gvhd: Both are donor T-cell manipulation strategies (allodepletion + suicide switch vs CD8 depletion) aimed at balancing immune reconstitution against GvHD post-transplant. (novelty: 4)
- Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: FDA Orphan Products Grants Program awarded Johns Hopkins $750,000 to develop CD8-reduced donor T cells targeting MDS/AML arising from MPN progression; no clinical outcomes data yet reported (funding announcement). (novelty: 3)
Open questions
Related
Contributing findings
FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases
Foundation announcement (recent)
novelty 3
per-area 4
introduces